2. Signaling Pathways
  3. Apoptosis
  4. ASK1

ASK1

Apoptosis signal-regulating kinase 1; MAP3K5; MAPKKK5; Mitogen-activated protein kinase kinase kinase 5; MEK kinase 5

Apoptosis signal-regulating kinase 1 (ASK1) is a member of the mitogen-activated protein kinase (MAP3K) family which acts as an upstream regulator for the activation of p38 MAPK and c-Jun N-terminal kinase (JNK). Under normal physiological conditions, ASK1 is maintained in an inactive state through binding to the reduced form of thioredoxin. However, during pathological conditions which induce intracellular production of reactive oxygen species (e.g., mitochondrial or endoplasmic reticulum stress), thioredoxin is oxidized and dissociates from ASK1 facilitating activation of ASK1 and downstream p38 MAPK and JNK signaling that can cause tissue injury .

ASK1 Related Products (14):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B1065
    Aceglutamide
    		Inhibitor ≥98.0%
    Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research.
    Aceglutamide
  • HY-131969
    ASK1-IN-2
    		Inhibitor 99.55%
    ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM. ASK1-IN-2 can be used for the research of ulcerative colitis.
    ASK1-IN-2
  • HY-133554
    ASK1-IN-1
    		Inhibitor 99.80%
    ASK1-IN-1 is a CNS-penetrant ASK1 (apoptosis signal-regulating kinase 1) inhibitor, with good potency (cell IC50=138 nM; Biochemical IC50=21 nM).
    ASK1-IN-1
  • HY-160851
    GDC-3280
    		Inhibitor 98.82%
    GDC-3280 (AK3287; AKEX0011) is an orally active compound based on Pirfenidone (HY-B0673)'s phenyl pyridone scaffold. GDC-3280 alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 MAPK pathway and regulating macrophage polarization. GDC-3280 exhibits anti-inflammatory and anti-fibrotic effects.
    GDC-3280
  • HY-160939
    ASK1-IN-6
    		Inhibitor 98.13%
    ASK1-IN-6 (Compound 32) is a selective inhibitor for apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 25 nM. ASK1-IN-6 is blood brain barrier penetrate(rat Cl/Clu is 1.6/56 L/h/kg and Kp,uu is 0.46). ASK1-IN-6 exhibits anti-inflammatory avtivity and ameliorates the Alzheimer’s Disease in Tg4510 mouse model.
    ASK1-IN-6
  • HY-173293
    ASK1-IN-8
    		Inhibitor
    ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of 1.8 nM. In an experimental mouse model of liver injury induced by Acetaminophen (HY-66005), ASK1-IN-8 can significantly reduce the plasma alanine transaminase (ALT) level, protecting the liver. ASK1-IN-8 can be used in research related to liver diseases.
    ASK1-IN-8
  • HY-174858
    dASK1-VHL
    		Degrader
    dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH) (Pink: ASK1 ligand 1 (HY-174860); Blue: E3 ligand (S,R,S)-AHPC (HY-125845); Black: Linker, (S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH (HY-174861).
    dASK1-VHL
  • HY-174860
    ASK1 ligand 1
    		Degrader
    ASK1 ligand 1 is a binding ligand for ASK1 and can be used to synthesize PROTACs such as dASK1-VHL (HY-174858)[1].
    ASK1 ligand 1
  • HY-153761
    ASK1-IN-4
    		Inhibitor
    ASK1-IN-4 (Compound 17) is an ASK1 inhibitor (IC50=0.2 μM). ASK1-IN-4 interacts with ATP-binding site of ASK1.
    ASK1-IN-4
  • HY-146729
    ASK1-IN-3
    		Inhibitor
    ASK1-IN-3 is a potent and selective ASK1 kinase inhibitor with IC50 of 33.8 nM, as well as inhibits several cell cycle regulating kinases. ASK1-IN-3 has strong HepG2 cancer cells apoptosis induction and potent cell cycle arrest activities.
    ASK1-IN-3
  • HY-174862
    dASK1
    		Degrader
    dASK1 is a selective and cereblon (CRBN)-based PROTAC degrader of apoptosis signal-regulating kinase 1 (ASK1). dASK1 forms a stable ternary complex with ASK1, facilitating ASK1 rapid and sustained degradation via the ubiquitin-proteasome pathway. dASK1 demonstrates potent ASK1 degradation. dASK1 can be used for the research of steatohepatitis. (Structure Note: Pink: ASK1 ligand (HY-174860); Blue: E3 ligase ligand (HY-10984); Black: linker; E3-linker (HY-174863))
    dASK1
  • HY-169555
    ASK1-IN-7
    		Inhibitor
    ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. ASK1-IN-7 holds promise for research related to the ASK1 signaling pathway, such as cell stress responses, inflammation, neurodegenerative diseases, and cardiovascular diseases.
    ASK1-IN-7
  • HY-18297
    ASK1-IN-5
    		Inhibitor
    ASK1-IN-5 (S-99) is an inhibitor of apoptosis signal-regulated kinase 1 (ASK1) and is useful in the study of autoimmune and neurodegenerative diseases.
    ASK1-IN-5
  • HY-B1065R
    Aceglutamide (Standard)
    		Inhibitor
    Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research.
    Aceglutamide (Standard)